BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONC BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

Market Closed 05-15 16:00:00 EDT

293.27

-11.35

-3.73%

盘后296.00

+2.73+0.93%

19:46 EDT

High299.98	Low293.09	Vol269.81K
Open299.98	D1 Closing304.62	Amplitude2.26%
Mkt Cap32.55B	Tradable Cap25.06B	Total Shares111.00M
T/O79.75M	T/O Rate0.32%	Tradable Shares85.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":293.27,"timestamp":1778875200000,"preClose":304.62,"halted":0,"volume":269809,"hourTrading":{"tag":"盘后","latestPrice":296,"preClose":293.27,"latestTime":"19:46 EDT","volume":1152,"amount":338251.69,"timestamp":1778888780613,"change":2.73,"changeRate":0.009309,"amplitude":0.009309},"delay":0,"changeRate":-0.03725953647166969,"floatShares":85449100,"shares":111000000,"eps":4.404108,"marketStatus":"Market Closed","change":-11.35,"latestTime":"05-15 16:00:00 EDT","open":299.98,"high":299.98,"low":293.09,"amount":79749893.29763,"amplitude":0.022618,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.404108,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779091200000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":304.62,"preHourTrading":{"tag":"盘前","latestPrice":299.98,"preClose":304.62,"latestTime":"09:28 EDT","volume":9180,"amount":2791248.9516,"timestamp":1778851680158,"change":-4.64,"changeRate":-0.015232,"amplitude":0.020255},"postHourTrading":{"tag":"盘后","latestPrice":296,"preClose":293.27,"latestTime":"19:46 EDT","volume":1152,"amount":338251.69,"timestamp":1778888780613,"change":2.73,"changeRate":0.009309,"amplitude":0.009309},"volumeRatio":1.063358488826511,"impliedVol":0.3876,"impliedVolPercentile":0.0478},"requestUrl":"/m/hq/s/ONC","defaultTab":"news","newsList":[{"id":"2635477088","title":"Beone Medicines : Leerink Partners Raises Target Price to $367 From $364","url":"https://stock-news.laohu8.com/highlight/detail?id=2635477088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635477088?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:09","pubTimestamp":1778839749,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nFWN41S0QC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK0239","ONC","688235","BK4139","BK4588","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717718","title":"Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717718?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761843,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nekt...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-iqvia-holdings-iqv-beone-medicines-onc-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-iqvia-holdings-iqv-beone-medicines-onc-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0130517989.USD","LU0198837287.USD","LU0528227936.USD","LU1201861165.SGD","LU0648000940.SGD","LU1791710582.SGD","BK4530","LU1201861249.SGD","LU1791710400.SGD","BK4585","HCSG","LU0130103400.USD","LU0130518102.USD","LU1989764748.USD","BK4526","XBI","BK4007","LU0648001328.SGD","BK4139","MDCO","LU0477156797.USD","LU1989764664.SGD","BK4588","LU0477156953.USD","ONC","BK4121","LU0130102774.USD","LU1261432733.SGD","NKTR","LU0029874061.USD","XLV","LU0128526141.USD","BK4581","LU0882574055.USD","LABU","LU0980610538.SGD","IQV","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185917537","title":"BEIGENE's BEQALZI™ Secures FDA Accelerated Approval as First and Only BCL2 Inhibitor for Relapsed/Refractory Mantle Cell Lymphoma in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=1185917537","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185917537?lang=en_us&edition=fundamental","pubTime":"2026-05-14 07:50","pubTimestamp":1778716222,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) announced that on May 13, 2026 (Eastern Time), BEQALZI™ (sotoclax) received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0588546209.SGD","LU1770034418.SGD","BK0239","LU1303224171.USD","ONC","BK1500","LU1719994722.HKD","BK4139","BK1583","BK1588","LU2328871848.SGD","BK4526","LU1251922891.USD","BK4588","06160","LABU","BK4585","LU0307460666.USD","688235","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635875862","title":"BeOne Medicines’ Beqalzi granted accelerated approval by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2635875862","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635875862?lang=en_us&edition=fundamental","pubTime":"2026-05-14 03:42","pubTimestamp":1778701379,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. Food and Drug Administration has granted accelerated approval to Beqalzi, a next-generation BCL2 inhi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-beqalzi-granted-accelerated-approval-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-beqalzi-granted-accelerated-approval-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","MDCO","BK4588","BK4139","BK4585","ONC","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635734776","title":"BeOne Medicines Gets FDA Accelerated Approval for Lymphoma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2635734776","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635734776?lang=en_us&edition=fundamental","pubTime":"2026-05-14 01:45","pubTimestamp":1778694300,"startTime":"0","endTime":"0","summary":"BeOne Medicines received accelerated approval from the Food and Drug Administration for Beqalzi, a treatment aimed at certain lymphoma patients.The oncology company said Wednesday the treatment got FDA approval for adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy.The accelerated approval is supported by data from a Phase 1/2 study that showed the treatment had an overall response rate of 52%, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","BK4526","ONC","MDCO","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176428606","title":"BEIGENE Announces Grant of Restricted Stock Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1176428606","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176428606?lang=en_us&edition=fundamental","pubTime":"2026-05-13 17:08","pubTimestamp":1778663295,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) has announced that on May 8, 2026, the Board's Compensation Committee granted a total of 25,436 American Depositary Shares in the form of Restricted Stock Units to 201 grantees under...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1588","LU1719994722.HKD","LU2328871848.SGD","LU1770034418.SGD","LU1303224171.USD","BK0239","BK1500","BK4588","LU0307460666.USD","LU1969619763.USD","06160","LU1251922891.USD","BK4139","BK1161","ONC","BK4585","LU0588546209.SGD","BK4526","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149089192","title":"BEIGENE Reports Q1 Profit Turnaround with 1.6 Billion Yuan Net Income","url":"https://stock-news.laohu8.com/highlight/detail?id=1149089192","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149089192?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497235,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) announced its first-quarter results for 2026. The group achieved operating revenue of 10.544 billion yuan, representing a year-on-year increase of 31.0%. Net profit attributable to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1500","LU1719994722.HKD","BK4526","ONC","LU0588546209.SGD","06160","LU1969619763.USD","LU1303224171.USD","BK4139","BK0239","LU0307460666.USD","BK1588","LU2328871848.SGD","BK1583","BK4588","688235","LU1251922891.USD","LU1770034418.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172603006","title":"CICC Maintains Outperform Rating on BEIGENE with HK$250 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1172603006","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172603006?lang=en_us&edition=fundamental","pubTime":"2026-05-08 10:10","pubTimestamp":1778206233,"startTime":"0","endTime":"0","summary":"CICC has issued a research report stating that, after comprehensive consideration of BEIGENE's (06160) expense control, it maintains its 2026 revenue forecast while raising its profit forecast by...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","BK1588","EWH","688235","BK1161","BK4526","BK4588","LU0307460666.USD","BK0239","BK4585","LU1251922891.USD","LU1303224171.USD","BK1583","LU1770034418.SGD","LU2328871848.SGD","LU1719994722.HKD","ONC","06160","LU1969619763.USD","LU0588546209.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180175339","title":"Leadership Reshuffle Sweeps Pharmaceutical Sector: Hengrui, Fosun, AstraZeneca, Pfizer Among Key Players","url":"https://stock-news.laohu8.com/highlight/detail?id=1180175339","media":"Deep News","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180175339?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:04","pubTimestamp":1778159091,"startTime":"0","endTime":"0","summary":"In the span of a single month, board reshuffles or senior management changes have occurred at no fewer than 14 pharmaceutical firms, including FOSUN PHARMA, HENGRUI PHARMA, BEIGENE, HBM HOLDINGS-B,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","SG9999002232.USD","IE00BBT3K403.USD","02196","LU0058720904.USD","LU0456855351.SGD","LU0868494617.USD","LU1023059063.AUD","LU2237443465.HKD","BK4007","BK4533","SG9999013999.USD","IE000M9KFDE8.USD","LU0225284248.USD","IE00B3T34201.USD","02142","LU0289739699.SGD","BK4592","LU0321505439.SGD","LU2236285917.USD","LU0320765992.SGD","IE0002270589.USD","LU1066051498.USD","SG9999011175.SGD","LU1066053197.SGD","BK4599","LU0225771236.USD","LU2237443382.USD","LU2237443978.SGD","LU1057294990.SGD","SG9999001176.USD","LU2237443549.SGD","LU0889565916.HKD","LU2417539215.USD","LU0306806265.USD","BK4588","IE00B19Z3581.USD","600196","AZNH","LU1894683264.USD","LU1894683348.USD","SG9999001176.SGD","LU1883839398.USD","SG9999002224.SGD","LU0122379950.USD","06160","01276","LU0306807586.USD","SG9999003800.SGD","BK4550","SGXZ57979304.SGD","ONC","LU2237443895.HKD","BK4585","IE00BLSP4239.USD","LU1829250122.USD","BK4581","BK4534","LU0985481810.HKD","LU2462157665.USD","IE00BLSP4452.SGD","AZN","LU2237443622.USD","PFE","600276","LU0170899867.USD","LU0321505868.SGD","LU0109394709.USD","IE00B19Z3B42.SGD","BK4568","LU2456880835.USD","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633194345","title":"BeOne Medicines Shares Surge After Robust First-Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2633194345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633194345?lang=en_us&edition=fundamental","pubTime":"2026-05-07 13:59","pubTimestamp":1778133540,"startTime":"0","endTime":"0","summary":"Shares of BeOne Medicines surged after the drugmaker reported a sharp increase in its first-quarter earnings.BeOne's Hong Kong-listed shares rose as much as 7.0% in early Thursday trading, while its Shanghai-listed shares rose 6.1%. Its H-shares and A-shares were last 3.2% and 3.3% higher, respectively.The pharmaceutical major said in an exchange filing late Wednesday that its first-quarter net income, on a GAAP basis, was $227.4 million, surging from $1.3 million in the same period a year earlier. Revenue rose 35%, driven by strong sales of its flagship cancer treatments, which the company said have become market leaders in the U.S. and are expanding in Europe.Adjusted earnings per share for the quarter was $3.24, it added.The strong results have bolstered the company's outlook, with chief executive officer John V. Oyler saying in its filing that the earnings \"reinforce BeOne's continued growth as a global oncology leader.\". The drugmaker has also raised its financial guidance for the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK4588","BK4585","MDCO","BK4139","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171575506","title":"BEIGENE's Q1 Net Profit Soars 399% Sequentially, Shares Jump 7% Post-Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1171575506","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171575506?lang=en_us&edition=fundamental","pubTime":"2026-05-07 10:31","pubTimestamp":1778121094,"startTime":"0","endTime":"0","summary":"Hong Kong's pharmaceutical sector showed signs of recovery during early trading on May 7. Leading innovative drug companies saw collective gains, with the Huabao Hang Seng Hong Kong Stock Connect...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1161","06160","LU1969619763.USD","LU1770034418.SGD","LU1251922891.USD","LU0307460666.USD","LU2328871848.SGD","ONC","BK1500","BK4526","520880","BK0239","LU1303224171.USD","BK1588","688235","BK1583","BK4139","LU1719994722.HKD","BK4588","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143294932","title":"BEIGENE Shares Surge Over 4% Post-Earnings on Stellar Q1 Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=1143294932","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143294932?lang=en_us&edition=fundamental","pubTime":"2026-05-07 09:34","pubTimestamp":1778117661,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) opened more than 4% higher following its earnings release. At the time of writing, the stock was up 4.07% to HK$189.4, with a turnover of HK$41.31 million. On May 6, BEIGENE reported...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1500","BK4526","LU1251922891.USD","LU1770034418.SGD","LU0307460666.USD","LU1719994722.HKD","BK4139","LU1303224171.USD","ONC","BK4585","LU1969619763.USD","BK4588","BK1583","LU0588546209.SGD","BK0239","BK1588","688235","LU2328871848.SGD","VXUS","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164415246","title":"Lithium Carbonate Spot Prices Surge Significantly; BEIGENE Reports 178-Fold Jump in Q1 Net Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=1164415246","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164415246?lang=en_us&edition=fundamental","pubTime":"2026-05-07 07:25","pubTimestamp":1778109909,"startTime":"0","endTime":"0","summary":"Lithium carbonate spot prices have experienced a substantial increase. On May 6th, prices approached the 200,000 yuan per ton mark, reaching a new cyclical high and decisively moving away from...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1303224171.USD","BK1500","IE00BYTNYN87.SGD","BK1240","01205","BK1545","HK0000165453.HKD","LU1770034418.SGD","00938","BK1161","IE00BYQNZ168.SGD","LU1719994722.HKD","SG9999011746.SGD","BK4139","BK1583","VXUS","LU0307460666.USD","IE00BZ08YS42.EUR","BK4526","BK1224","BK1588","HK0000288743.USD","06162","BK4585","BK1124","BK1230","BK1589","BK1601","IE00BZ08YR35.GBP","LU1251922891.USD","LU2328871848.SGD","IE00B12V2V27.USD","BK1502","01177","HK0000288784.HKD","BK1144","BK1521","BK1191","BK0239","BK1515","BK1602","BK4588","01929","LU1969619763.USD","LU0588546209.SGD","06160","ONC","IE00BZ08YT58.USD","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116633664","title":"Stock Track | BeOne Medicines Soars 5.19% Intraday on Strong Q1 2026 Earnings and Positive Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1116633664","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116633664?lang=en_us&edition=fundamental","pubTime":"2026-05-06 23:19","pubTimestamp":1778080759,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. (NASDAQ: ONC) saw its stock price soar 5.19% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results that showed substantial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165111253","title":"BEIGENE Reports Q1 2026 Net Profit of 1.608 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1165111253","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165111253?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:41","pubTimestamp":1778067701,"startTime":"0","endTime":"0","summary":"BEIGENE (688235.SH) announced its financial results for the first quarter of 2026. The company reported product revenue of 10.321 billion yuan, representing a year-on-year increase of 29.3%. Total...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK4585","LU1770034418.SGD","LU1251922891.USD","LU1719994722.HKD","LU1303224171.USD","BK1583","BK1161","BK1500","BK4139","LU0307460666.USD","BK4588","LU2328871848.SGD","LU1969619763.USD","BK0239","ONC","06160","BK1588","BK4526","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633186920","title":"GUIDANCE: (ONC) BeOne Medicines Expects 2026 Revenue Range $6.3B - $6.5B, vs. FactSet Est of $6.4B","url":"https://stock-news.laohu8.com/highlight/detail?id=2633186920","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633186920?lang=en_us&edition=fundamental","pubTime":"2026-05-06 18:10","pubTimestamp":1778062220,"startTime":"0","endTime":"0","summary":"GUIDANCE: (ONC) BeOne Medicines Expects 2026 Revenue Range $6.3B - $6.5B, vs. FactSet Est of $6.4B","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633185201","title":"Press Release: BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633185201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633185201?lang=en_us&edition=fundamental","pubTime":"2026-05-06 18:00","pubTimestamp":1778061600,"startTime":"0","endTime":"0","summary":"--  Total global revenues of $1.5 billion for the first quarter, an. --  Foundational BRUKINSA  global revenues of $1.1 billion. for the first quarter, an increase of 38% from the prior year. --  Diluted GAAP Earnings per American Depository Share  of $1.96 for. the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the. BeOne Medicines Ltd. , a global oncology company, today announced financial results and corporate updates from the first quarter of 2026.John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:. Net product revenues   $     1,487,329   $     1,108,530        34%. GAAP net income        $       227,357   $         1,270    17,802%. Adjusted net income*   $       375,042   $       136,137       175%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","MDCO","BK4585","BK4526","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633575972","title":"Is It Too Late To Consider BeOne Medicines (ONC) After Its 23% One Year Gain?","url":"https://stock-news.laohu8.com/highlight/detail?id=2633575972","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633575972?lang=en_us&edition=fundamental","pubTime":"2026-05-06 10:28","pubTimestamp":1778034535,"startTime":"0","endTime":"0","summary":"Wondering if BeOne Medicines at around US$297.49 is still offering value after a strong run? This article focuses squarely on what that price might really represent.\nThe stock has returned 23.1% over the past year. The shorter term picture shows a 0.2% slip over 7 days, 4.3% over 30 days and 4.4% year to date.\nRecent news around BeOne Medicines has kept attention on the stock, with investors weighing how company developments align with its current share price. These headlines help frame...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-it-too-late-to-consider-beone-medicines-onc-after-its-23","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-it-too-late-to-consider-beone-medicines-onc-after-its-23","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","ONC","BK4585","MDCO","BK4526","BK4139","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632364049","title":"BeOne Medicines AG  expected to post earnings of 87 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632364049","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632364049?lang=en_us&edition=fundamental","pubTime":"2026-05-04 16:02","pubTimestamp":1777881732,"startTime":"0","endTime":"0","summary":"BeOne Medicines AG  expected to post earnings of87cents a share - Earnings Preview BeOne Medicines AG ONC.OQ, ONC.O is expected to  show a rise in quarterly revenue when it reports  results  for the p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H0G1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK4588","ONC","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631487435","title":"BeOne Medicines Receives US FDA Priority Review for Tevimbra Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2631487435","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631487435?lang=en_us&edition=fundamental","pubTime":"2026-04-29 22:07","pubTimestamp":1777471649,"startTime":"0","endTime":"0","summary":"BeOne Medicines'  supplemental biologics license application for Tevimbra, in combination with Ziihera and chemotherapy, was granted priority review designation by the US Food and Drug Administration, the company said Wednesday.This drug is for patients with a specific type of stomach or throat cancer that has spread or cannot be removed by surgery. It specifically targets tumors that test positive for a protein called HER2, which helps the cancer grow.Interim data from a phase 3 trial of the combination therapy supported the application, with the Tevimbra combination demonstrating statistically significant improvement in overall survival and progression-free survival, the company said.The combination therapy's safety findings in the trial were generally consistent with the component's known effects, BeOne Medicines added.Price: 296.42, Change: -1.74, Percent Change: -0.58","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","BK4139","BK4526","ONC","MDCO","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":-0.0604},{"period":"1month","weight":-0.0834},{"period":"3month","weight":-0.1526},{"period":"6month","weight":-0.1983},{"period":"1year","weight":0.299},{"period":"ytd","weight":-0.0347}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.083709},{"month":2,"riseRate":0.6,"avgChangeRate":0.027535},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.02929},{"month":4,"riseRate":0.363636,"avgChangeRate":0.018832},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.017974},{"month":6,"riseRate":0.5,"avgChangeRate":0.012468},{"month":7,"riseRate":0.8,"avgChangeRate":0.147208},{"month":8,"riseRate":0.6,"avgChangeRate":0.034201},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","securityTypeName":"DR","adrRate":"1:13"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS,ONC,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎国际,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股价,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股市,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票价格,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票交易,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票购买,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}